Ocular composition and method
An ocular composition can include a polymer matrix and an antibiotic dispersed in the polymer matrix. The polymer matrix can contain a thiolated hyaluronic acid moiety cross-linked to a second moiety. The composition can be configured for placement in or on an eye of a subject to provide controlled release of the antibiotic to the eye. A method of treating or preventing an ocular disease can include providing an ocular composition and applying the ocular composition to a surface of an eye of a subject to provide controlled release of the antibiotic to the eye. The ocular composition can include a polymer matrix and an antibiotic dispersed in the polymer matrix. The polymer matrix can include a thiolated hyaluronic acid moiety cross-linked to a second moiety.
1. An ocular composition, comprising:
a polymer matrix comprising a thiolated hyaluronic acid moiety cross-linked to a second moiety, wherein the second moiety is a poly(ethylene glycol) diacrylate moiety; and
an antimicrobial dispersed in the polymer matrix at a dosage sufficient to inhibit microbial growth;
wherein the composition is configured for placement in or on an eye of a subject, and wherein the composition provides controlled release of from 0.5 μg to 50 μg per day of the antimicrobial to the eye over a period of from 1 week to 8 weeks.
2. The ocular composition of claim 1 , wherein the composition is formulated as an ocular insert, an implantable depot, a topical formulation, a spray formulation, an injectable fluid, a microparticle suspension, a nanoparticle suspension, a monolithic rod, a film, a gel, a sponge, or a combination thereof.
3. The ocular composition of claim 1 , wherein the ocular composition is formulated as a film for placement on a surface of the eye.
4. The ocular composition of claim 3 , wherein the film contains from about 30 μg to about 500 μg of the antimicrobial.
5. The ocular composition of claim 3 , wherein the film has a diameter from about 2 mm to about 16 mm and a thickness from about 0.05 mm to about 3 mm.
6. The ocular composition of claim 1 , wherein the antimicrobial is incorporated into the thiolated hyaluronic acid moiety and second moiety before cross-linking, such that the antimicrobial is trapped within the polymer matrix after cross-linking.
7. The ocular composition of claim 1 , wherein the second moiety comprises a cross-linking group capable of cross-linking with a thiol group of the thiolated hyaluronic acid moiety, and wherein the thiolated hyaluronic acid moiety and second moiety are present in amounts such that a ratio of thiol groups to cross-linking groups is from 1:1 to 2.5:1.
8. The ocular composition of claim 1 , further comprising an antiviral, antifungal, anti-inflammatory steroid, non-steroidal anti-inflammatory, analgesic, artificial tears solution, decongestant, anticholinesterase, glaucoma hypotensive agent, antiangiogenesis agent, antiallergenic, anti-cancer agent or any combination thereof dispersed in the polymer matrix.
9. The ocular composition of claim 1 , wherein the polymer matrix comprises a bioerodible polymer that erodes to provide a rate of controlled release.
10. The ocular composition of claim 1 , wherein the polymer matrix further comprises at least one monomer selected from the group consisting of glycolic acid, glycolide, lactic acid, lactide, e-caprolactone, p-dioxane, p-diozanone, trimethlyenecarbonate, bischloroformate, ethylene glycol, bis(p-carboxyphenoxy) propane, sebacic acid, and combinations thereof.
11. The ocular composition of claim 1 , wherein the thiolated hyaluronic acid moiety is a thiolated carboxymethyl hyaluronic acid moiety.
12. The ocular composition of claim 1 , wherein the antimicrobial is an antibiotic and the antibiotic is selected from the group consisting of aminoglycosides, penicillins, cephalosporins, fluoroquinolones, macrolides, and combinations thereof.
13. The ocular composition of claim 12 , wherein the antibiotic is an aminoglycoside selected from the group consisting of tobramycin, kanamycin A, amikacin, dibekacin, gentamicin, sisomicin, netilmicin, neomycin B, neomycin C, neomycin E, streptomycin, and combinations thereof.
14. The ocular composition of claim 12 , wherein the antibiotic is at least one of tobramycin and vancomycin.
15. The ocular composition of claim 12 , wherein the antibiotic is a fluoroquinolone selected from the group consisting of ciprofloxacin, levofloxacin, gatifloxacin, moxifloxacin, ofloxacin, norfloxacin, and combinations thereof.
16. The ocular composition of claim 12 , wherein the antibiotic is moxifloxacin.
17. The ocular composition of claim 1 , wherein the antimicrobial has a concentration in the polymer matrix from about 1 μg to about 27 μg per milliliter.
18. The ocular composition of claim 1 , wherein the antimicrobial is an antifungal.
19. The ocular composition of claim 1 , wherein the antimicrobial is an antiviral.
20. The ocular composition of claim 1 , wherein the controlled release is over a period of from 1 week to 2 weeks.
21. A method of treating or preventing an ocular disease, comprising:
providing an ocular composition comprising:
a polymer matrix comprising a thiolated hyaluronic acid moiety cross-linked to a second moiety, wherein the second moiety is a poly(ethylene glycol) diacrylate moiety; and
an antimicrobial dispersed in the polymer matrix at a dosage sufficient to inhibit microbial growth; and
applying the ocular composition to a surface of an eye of a subject to provide a controlled release of from 0.5 μg to 50 μg per day the antimicrobial to the eye over a period of from 1 week to 8 weeks.
22. The method of claim 21 , wherein the antimicrobial is released continuously.
23. The method of claim 21 , wherein applying the ocular composition to the eye comprises placing the ocular composition under a contact lens or bandage lens worn in the eye.
24. The method of claim 21 , wherein the ocular composition is an ocular insert, solution, film, or gel.